David Grayzel
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About David Grayzel
David Grayzel was last confirmed as Board Member at Q32 Bio Inc. (QTTB) in a filing dated April 29, 2025. Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that David Grayzel resigned as Aerovate's board of directors, effective April 28, 2025. Q32 Bio Inc. reported in an 8-K filed March 27, 2024 that David Grayzel was appointed Class I director, effective March 25, 2024.
“On April 28, 2025, Timothy Noyes, Habib Dable, Allison Dorval, David Grayzel, M.D., Mark Iwicki, Joshua Resnick, M.D. and Donald Santel resigned from Aerovate's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.”
“Dr. Grayzel, Mr. Xu and Dr. Manke were appointed as Class I directors (terms expire at our 2025 annual meeting)”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2024-01-01–2025-04-29
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.